Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Tiotropium (Spiriva® Respimat®) is recommended as an option for use within NHS Wales as add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma who experienced one or more severe asthma exacerbations in the preceding year. |
|||
|
|||
Medicine details |
|||
| Medicine name | tiotropium (Spiriva® Respimat®) | ||
| Formulation | 2.5 microgram inhalation solution | ||
| Reference number | 1882 | ||
| Indication | Add-on maintenance bronchodilator treatment in patients aged 6 years to < 18 years with severe asthma who experienced one or more severe asthma exacerbations in the preceding year |
||
| Company | Boehringer Ingelheim Ltd | ||
| BNF chapter | Respiratory system | ||
| Submission type | Limited | ||
| Status | Recommended | ||
| Advice number | 2118 | ||
| NMG meeting date | 10/10/2018 | ||
| AWMSG meeting date | 14/11/2018 | ||
| Date of issue | 03/12/2018 | ||
| Date of last review | April 2022 | ||
| Further information This advice incorporates and replaces the AWMSG recommendation for tiotropium (Spiriva® Respimat® ) as an option for use within NHS Wales as an add-on maintenance bronchodilator treatment in adult patients with asthma who are currently treated with the maintenance combination of inhaled corticosteroids (≥ 800 micrograms budesonide daily or equivalent) and long acting beta2-agonists and who experienced one or more severe exacerbations in the previous year (Advice number 2317, originally published October 2017). This appraisal recommendation was reviewed in April 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG’s static list of medicine recommendations. |
|||